Ingested (oral) SST inhibits EAE.
Ingested immunoactive proteins type I interferon, soluble immune response suppressor peptide 1-21 and melanocyte-stimulating hormone inhibit clinical attacks and inflammation in acute experimental autoimmune encephalomyelitis (EAE). We examined whether another immunoactive protein, somatostatin (SST), would have similar anti-inflammatory effects on EAE after oral administration. B6 mice were immunized with MOG peptide 35-55 and gavaged with control saline or SST during ongoing disease. Splenocytes from mock-fed or SST-fed mice were adoptively transferred into active MOG peptide 35-55-immunized recipient mice during ongoing disease. In actively fed mice, increased Th2-like cytokines in both the spleen and the central nervous system (CNS) inhibited active disease. In recipients of donor cells from SST-fed donors, reduction of Th1 and Th17 and induction of Th2-like IL-4 cytokines in both the spleen and CNS inhibited disease. T(reg) cells were increased threefold in actively fed spleen cells that are responsible for protection against disease after adoptive transfer. Ingested (orally administered) SST can inhibit clinical disease, inhibit CNS inflammation by decreasing Th17 and Th1-like cytokines and increasing Th2-like cytokines in the CNS via induction of T(reg) cells.